Breast percentage density estimations with synthesized 2D breast imaging versus standard-dose mammograms.
Synthesized digital breast tomosynthesis (DBT) images are generally comparable to images from standard-dose mammograms, according to a study published in Radiology.
Researchers from the University of Pennsylvania in Philadelphia compared the quality and agreement between automated estimates of breast density made from standard-dose versus synthetic digital mammograms among women undergoing breast cancer screening.
The researchers evaluated images taken from 3,668 negative digital breast tomosynthesis (DBT) screening examinations consecutively performed over a four-month period, in which both standard-dose and synthesized mammograms were available. Agreement between density estimates was assessed by using Pearson correlation, linear regression, and Bland-Altman analysis. Differences were evaluated by using the paired Student t test.
Results showed that breast percentage density (PD) estimates from synthetic and standard-dose mammograms were highly correlated, and the 95% Bland-Altman limits of agreement between PD estimates were −6.4% to 9.9%. Synthetic mammograms had PD estimates by an average of 1.7% higher than standard-dose mammograms, with a larger disagreement by 1.56% in women with highly dense breast tissue.
“Fully automated estimates of breast density made from synthetic mammograms are generally comparable to those made from standard-dose mammograms,” the researchers concluded. “This may be important, as standard two-dimensional mammographic images are increasingly being replaced by synthetic mammograms in DBT screening in an attempt to reduce radiation dose.”
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.